Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Gains from Investment Securities (2020 - 2025)

Oncology Institute (TOI) has disclosed Gains from Investment Securities for 6 consecutive years, with -$68000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 1233.33% year-over-year to -$68000.0, compared with a TTM value of -$618000.0 through Sep 2025, down 3190.0%, and an annual FY2024 reading of -$619000.0, down 836.9% over the prior year.
  • Gains from Investment Securities was -$68000.0 for Q3 2025 at Oncology Institute, down from $94000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.7 million in Q4 2021 and bottomed at -$646000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $176777.8, with a median of -$2500.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities skyrocketed 457.14% in 2023, then plummeted 9128.57% in 2024.
  • Year by year, Gains from Investment Securities stood at $3.7 million in 2021, then plummeted by 84.01% to $595000.0 in 2022, then plummeted by 101.18% to -$7000.0 in 2023, then tumbled by 9128.57% to -$646000.0 in 2024, then surged by 89.47% to -$68000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for TOI at -$68000.0 in Q3 2025, $94000.0 in Q2 2025, and $2000.0 in Q1 2025.